Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06889493 · ClinicalTrials.gov registry record · Phase 1
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
A Phase 1 study of Neuroendocrine Tumors and Neuroendocrine Carcinoma, sponsored by Peter Hosein, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT06889493: Recruiting Phase 1 study of Neuroendocrine Tumors and Neuroendocrine Carcinoma, sponsored by Peter Hosein, MD.
NCT06889493 is a Phase 1 study of Neuroendocrine Tumors and Neuroendocrine Carcinoma that is actively recruiting participants, run by Peter Hosein, MD. The registered enrollment target is 36 participants, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06889493, a Phase 1 study of Neuroendocrine Tumors and Neuroendocrine Carcinoma, is actively recruiting participants, sponsored by Peter Hosein, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine: 1. The highest dose of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. 2. The highest frequency of dosing of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. 3. The highest dose and frequency of dosing of the trial intervention that targets neuroendocrine tumors with at least the same degree of effectiveness and tolerability as currently available (standard of care) treatments for patients with neuroendocrine tumors.
Primary Outcome
MTD is defined as the highest dose of SVV-001 evaluated for which estimated toxicity rate is the closest to the target toxicity rate as assessed by treating physician using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The MTD will be established as the recommended phase 2 dose (RP2D).
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- BIOLOGICAL Seneca Valley Virus-001 (SVV-001)
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-05-19 |
| Est. Completion | 2030-06-01 |
| Phase | Phase 1 |
What NCT06889493 shows while recruiting
NCT06889493 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT06889493 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06889493 about?
NCT06889493 is a clinical study titled "SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)". The purpose of this study is to determine: 1. The highest dose of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. 2. The highest frequency of dosing of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. 3. The highest dose...
What is the current status of trial NCT06889493?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2025-05-19. Estimated completion is 2030-06-01.
What conditions does trial NCT06889493 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors, Neuroendocrine Carcinoma.
What interventions are being tested in trial NCT06889493?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Seneca Valley Virus-001 (SVV-001) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06889493?
This trial is sponsored by Peter Hosein, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06889493 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06889493's enrollment target sits among peer trials
36 35th of 52 higher than 18 of 52 other Neuroendocrine Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroendocrine Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
RECRUITING · Phase 1
-
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
RECRUITING · Phase 1
-
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
RECRUITING · Phase 1
-
177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI